Last kr18.30 SEK
Change Today +0.20 / 1.10%
Volume 64.4K
ACTI On Other Exchanges
Symbol
Exchange
Stuttgart
Stockholm
OTC US
OTC US
As of 11:29 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Open
kr18.10
Previous Close
kr18.10
Day High
kr18.70
Day Low
kr18.00
52 Week High
02/26/14 - kr38.23
52 Week Low
12/16/14 - kr15.50
Market Cap
1.6B
Average Volume 10 Days
140.4K
EPS TTM
kr-3.24
Shares Outstanding
89.9M
EX-Date
02/15/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ), a biotechnology company, focuses on developing pharmaceuticals for the treatment of autoimmune/inflammatory diseases and cancer in Sweden. Its projects include Laquinimod, an orally administered compound in Phase III clinical trial development for the treatment of autoimmune diseases, primarily multiple sclerosis; Tasquinimod, which is in Phase III clinical trial for the treatment of prostate cancer; and ANYARA, a protein drug in Phase II/III study for the treatment of renal cell cancer. The company is also developing Paquinimod (57-57), a compound primarily for the treatment of systemic sclerosis; and RhuDex, a compound that is primarily intended to be used as a drug for the treatment of rheumatoid arthritis. Its preclinical project product is ISI (inhibition of S100 interactions) for producing patentable chemical compounds that interact with S100A9, a target molecule for the quinoline compounds. Active Biotech AB (publ) is headquartered in Lund, Sweden.

58 Employees
Last Reported Date: 12/5/14

active biotech ab (ACTI) Top Compensated Officers

President and Chief Executive Officer
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Active Biotech AB Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM

Active Biotech AB Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Tomas Leanderson, President and Chief Executive Officer.

Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended of September 2014

Active Biotech AB reported earnings results for the third quarter and nine months ended of September 2014. For the quarter, the company reported net sales of SEK 2.6 million compared to SEK 107.0 million a year ago. Operating loss was SEK 55.7 million compared to operating income of SEK 27.9 million a year ago. Loss for the period was SEK 56.6 million compared to income for the period of SEK 29.2 million a year ago. Before and after dilution loss per share was SEK 0.76 compared to earnings per share before and after dilution was SEK 0.39 a year ago. For the nine months, the company reported net sales of SEK 7.5 million compared to SEK 111.9 million a year ago. Operating loss was SEK 172.8 million compared to operating loss of SEK 128.6 million a year ago. Loss for the period was SEK 174.5 million compared to loss for the period of SEK 130.0 million a year ago. Before and after dilution loss per share was SEK 2.33 compared to loss per share before and after dilution was SEK 1.77 a year ago.

Active Biotech AB, Special/Extraordinary Shareholders Meeting, Dec 01, 2014

Active Biotech AB, Special/Extraordinary Shareholders Meeting, Dec 01, 2014., at 17:00 Central European Standard Time. Location: Scheelevägen 22.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr18.30 SEK +0.20

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies
 

Industry Analysis

ACTI

Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 102.2x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit www.activebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.